Recipharm commences new supply contract and completes purchase of facility in Spain
Recipharm AB announces that it has today commenced the supply of commercial products to Roche and completed the acquisition of the manufacturing facility located in Leganés, Spain.
Thomas Eldered, CEO of Recipharm commented: “We are continuing to gain momentum in the CDMO market and this latest agreement is another demonstration of this. I welcome our new colleagues in Spain and look forward to providing Roche with first-class CDMO services”.
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Henrik Stenqvist, CFO, firstname.lastname@example.org , telephone: +46 8 602 52 00
This information is information that Recipharm AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 1 December 2017, at 13:00 CET.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00